Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate

Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ryan Smith [verfasserIn] Jake Fantus [verfasserIn] Ella J. Doerge [verfasserIn] Larry Lipshultz [verfasserIn] Jason R. Kovac [verfasserIn] Robert Coward [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017

Übergeordnetes Werk:	In: Journal of Men's Health - MRE Press, 2018, 11(2017), 5
Übergeordnetes Werk:	volume:11 ; year:2017 ; number:5

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ027190072

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ027190072
003	DE-627
005	20240413084515.0
007	cr uuu---uuuuu
008	230226s2017 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ027190072
035			\|a (DE-599)DOAJc577c080a8944d18871f863258e487c0
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Ryan Smith \|e verfasserin \|4 aut
245	1	0	\|a Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.
653		0	\|a Medicine (General)
700	0		\|a Jake Fantus \|e verfasserin \|4 aut
700	0		\|a Ella J. Doerge \|e verfasserin \|4 aut
700	0		\|a Larry Lipshultz \|e verfasserin \|4 aut
700	0		\|a Jason R. Kovac \|e verfasserin \|4 aut
700	0		\|a Robert Coward \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Men's Health \|d MRE Press, 2018 \|g 11(2017), 5 \|w (DE-627)568291832 \|w (DE-600)2428850-0 \|x 18756859 \|7 nnns
773	1	8	\|g volume:11 \|g year:2017 \|g number:5
856	4	0	\|u https://doaj.org/article/c577c080a8944d18871f863258e487c0 \|z kostenfrei
856	4	0	\|u http://jomh.org/index.php/JMH/article/view/14 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1875-6859 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 11 \|j 2017 \|e 5

Indexfelder

author_variant	r s rs j f jf e j d ejd l l ll j r k jrk r c rc
matchkey_str	article:18756859:2017----::aeiespeitsmnaaeersosiifriee
hierarchy_sort_str	2017
callnumber-subject-code	R
publishDate	2017
allfields	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0 DE-627 ger DE-627 rakwb eng R5-920 Ryan Smith verfasserin aut Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Medicine (General) Jake Fantus verfasserin aut Ella J. Doerge verfasserin aut Larry Lipshultz verfasserin aut Jason R. Kovac verfasserin aut Robert Coward verfasserin aut In Journal of Men's Health MRE Press, 2018 11(2017), 5 (DE-627)568291832 (DE-600)2428850-0 18756859 nnns volume:11 year:2017 number:5 https://doaj.org/article/c577c080a8944d18871f863258e487c0 kostenfrei http://jomh.org/index.php/JMH/article/view/14 kostenfrei https://doaj.org/toc/1875-6859 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2017 5
spelling	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0 DE-627 ger DE-627 rakwb eng R5-920 Ryan Smith verfasserin aut Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Medicine (General) Jake Fantus verfasserin aut Ella J. Doerge verfasserin aut Larry Lipshultz verfasserin aut Jason R. Kovac verfasserin aut Robert Coward verfasserin aut In Journal of Men's Health MRE Press, 2018 11(2017), 5 (DE-627)568291832 (DE-600)2428850-0 18756859 nnns volume:11 year:2017 number:5 https://doaj.org/article/c577c080a8944d18871f863258e487c0 kostenfrei http://jomh.org/index.php/JMH/article/view/14 kostenfrei https://doaj.org/toc/1875-6859 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2017 5
allfields_unstemmed	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0 DE-627 ger DE-627 rakwb eng R5-920 Ryan Smith verfasserin aut Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Medicine (General) Jake Fantus verfasserin aut Ella J. Doerge verfasserin aut Larry Lipshultz verfasserin aut Jason R. Kovac verfasserin aut Robert Coward verfasserin aut In Journal of Men's Health MRE Press, 2018 11(2017), 5 (DE-627)568291832 (DE-600)2428850-0 18756859 nnns volume:11 year:2017 number:5 https://doaj.org/article/c577c080a8944d18871f863258e487c0 kostenfrei http://jomh.org/index.php/JMH/article/view/14 kostenfrei https://doaj.org/toc/1875-6859 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2017 5
allfieldsGer	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0 DE-627 ger DE-627 rakwb eng R5-920 Ryan Smith verfasserin aut Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Medicine (General) Jake Fantus verfasserin aut Ella J. Doerge verfasserin aut Larry Lipshultz verfasserin aut Jason R. Kovac verfasserin aut Robert Coward verfasserin aut In Journal of Men's Health MRE Press, 2018 11(2017), 5 (DE-627)568291832 (DE-600)2428850-0 18756859 nnns volume:11 year:2017 number:5 https://doaj.org/article/c577c080a8944d18871f863258e487c0 kostenfrei http://jomh.org/index.php/JMH/article/view/14 kostenfrei https://doaj.org/toc/1875-6859 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2017 5
allfieldsSound	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0 DE-627 ger DE-627 rakwb eng R5-920 Ryan Smith verfasserin aut Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters. Medicine (General) Jake Fantus verfasserin aut Ella J. Doerge verfasserin aut Larry Lipshultz verfasserin aut Jason R. Kovac verfasserin aut Robert Coward verfasserin aut In Journal of Men's Health MRE Press, 2018 11(2017), 5 (DE-627)568291832 (DE-600)2428850-0 18756859 nnns volume:11 year:2017 number:5 https://doaj.org/article/c577c080a8944d18871f863258e487c0 kostenfrei http://jomh.org/index.php/JMH/article/view/14 kostenfrei https://doaj.org/toc/1875-6859 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2017 5
language	English
source	In Journal of Men's Health 11(2017), 5 volume:11 year:2017 number:5
sourceStr	In Journal of Men's Health 11(2017), 5 volume:11 year:2017 number:5
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medicine (General)
isfreeaccess_bool	true
container_title	Journal of Men's Health
authorswithroles_txt_mv	Ryan Smith @@aut@@ Jake Fantus @@aut@@ Ella J. Doerge @@aut@@ Larry Lipshultz @@aut@@ Jason R. Kovac @@aut@@ Robert Coward @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	568291832
id	DOAJ027190072
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027190072</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413084515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027190072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc577c080a8944d18871f863258e487c0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ryan Smith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jake Fantus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ella J. Doerge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Larry Lipshultz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jason R. Kovac</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Coward</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Men's Health</subfield><subfield code="d">MRE Press, 2018</subfield><subfield code="g">11(2017), 5</subfield><subfield code="w">(DE-627)568291832</subfield><subfield code="w">(DE-600)2428850-0</subfield><subfield code="x">18756859</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c577c080a8944d18871f863258e487c0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://jomh.org/index.php/JMH/article/view/14</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1875-6859</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ryan Smith
spellingShingle	Ryan Smith misc R5-920 misc Medicine (General) Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
authorStr	Ryan Smith
ppnlink_with_tag_str_mv	@@773@@(DE-627)568291832
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	18756859
topic_title	R5-920 Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
topic	misc R5-920 misc Medicine (General)
topic_unstemmed	misc R5-920 misc Medicine (General)
topic_browse	misc R5-920 misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Men's Health
hierarchy_parent_id	568291832
hierarchy_top_title	Journal of Men's Health
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)568291832 (DE-600)2428850-0
title	Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
ctrlnum	(DE-627)DOAJ027190072 (DE-599)DOAJc577c080a8944d18871f863258e487c0
title_full	Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
author_sort	Ryan Smith
journal	Journal of Men's Health
journalStr	Journal of Men's Health
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
author_browse	Ryan Smith Jake Fantus Ella J. Doerge Larry Lipshultz Jason R. Kovac Robert Coward
container_volume	11
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Ryan Smith
author2-role	verfasserin
title_sort	baseline fsh predicts semen parameter response in infertile men on clomiphene citrate
callnumber	R5-920
title_auth	Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
abstract	Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.
abstractGer	Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.
abstract_unstemmed	Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	5
title_short	Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate
url	https://doaj.org/article/c577c080a8944d18871f863258e487c0 http://jomh.org/index.php/JMH/article/view/14 https://doaj.org/toc/1875-6859
remote_bool	true
author2	Jake Fantus Ella J. Doerge Larry Lipshultz Jason R. Kovac Robert Coward
author2Str	Jake Fantus Ella J. Doerge Larry Lipshultz Jason R. Kovac Robert Coward
ppnlink	568291832
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	R5-920
up_date	2024-07-04T00:44:38.056Z
_version_	1803607215238545408
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027190072</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413084515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027190072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc577c080a8944d18871f863258e487c0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ryan Smith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Clomiphene citrate (CC) is a selective estrogen receptor modulator that increases gonadotropin production and may improve spermatogenesis. The purpose of the study was to examine the effects of CC on hormone levels and spermatogenesis in men treated for infertility, and to determine whether it is possible to predict positive treatment outcomes, in terms of hormonal or spermatogenic response to CC prior to treatment. Methods: The cases of 90 men, who were prescribed CC for infertility, were retrospectively reviewed. Serum values for follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), estradiol (E) as well as complete semen analyses were collected before and after CC. Exclusion criteria included azoospermia and men treated with testosterone, human chorionic gonadotropin, or recombinant FSH during the previous 6 months. Results: Forty-two men (46.7%) with a mean age of 35±6years met the inclusion criteria for analysis. Serum hormone values significantly (p<0.01) increased for FSH (_3.4 mIU/ mL), LH (_2.7 mIU/mL), TT (_250.0 ng/dL), FT (_5.2 ng/dL), SHBG (_5.2nmoI/L) and E (_1.9 ng/dL). Patients with a baseline FSH of _2 mIU/mL had no change in sperm density (_-13.1±32.0 million/mL) or total motile count (_-20.6 ± 45.5 million). Men with an initial FSH<2 (n=32) had a mean change in density of +1.68±7.46 million/mL and demonstrated significant improvement in total motile sperm (_+3.4±13.96 million). There were no significant differences between the serum hormone levels in men with baseline FSH levels of _2 or <2 mIU/mL. Conclusions: Infertile men exhibit significant increases in serum hormone levels with CC. Those with FSH <2 mIU/mL had improved sperm density and motility relative to men with FSH _2mIU/mL. FSH prior to initiating CC therapy may be a useful predictor of improvement in semen parameters.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jake Fantus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ella J. Doerge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Larry Lipshultz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jason R. Kovac</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Coward</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Men's Health</subfield><subfield code="d">MRE Press, 2018</subfield><subfield code="g">11(2017), 5</subfield><subfield code="w">(DE-627)568291832</subfield><subfield code="w">(DE-600)2428850-0</subfield><subfield code="x">18756859</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c577c080a8944d18871f863258e487c0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://jomh.org/index.php/JMH/article/view/14</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1875-6859</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield></datafield></record></collection>
score	7.3994217

Nicht das Richtige dabei?

Schreiben Sie uns!

Baseline FSH Predicts Semen Parameter Response in Infertile Men on Clomiphene Citrate

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?